Shire has acquired Premacure AB of Uppsala, Sweden, a privately held biotechnology company, for an undisclosed upfront payment and development and commercial milestones. Premacure has a protein replacement therapy currently in Phase II for the prevention of retinopathy of prematurity (ROP), a rare and potentially blinding eye disorder that primarily affects premature infants. Currently only symptomatic treatment is available for ROP. The acquisition expands Shire’s therapeutic area into neonatol...